DP
RLAY icon

Diadema Partners’s Relay Therapeutics RLAY Stock Holding History

Diadema Partners’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-131,400
Closed -$344K – 124
2025
Q1 		$344K Buy
131,400
+31,400
+31% +$123K 0.09% 87
2024
Q4 		$412K Buy
+100,000
New +$544K 0.18% 76

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Diadema Partners's RLAY Position: Q2 2026 in Review

Diadema Partners opened a new position in Relay Therapeutics (RLAY) in Q2 2026: 230,677 shares worth $4.32M. The stake represents 0.55% of the portfolio and ranks #49 among its holdings. This is a return to the name: Diadema Partners previously reported a position in RLAY as recently as Q3 2025.

Diadema Partners first reported a position in RLAY in Q4 2024 and has held it in 5 quarters since. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Diadema Partners held 230,677 shares of Relay Therapeutics worth $4.32M as of Q2 2026.
  • Relay Therapeutics was a new Diadema Partners position in Q2 2026.
  • Relay Therapeutics made up 0.55% of Diadema Partners's portfolio in Q2 2026, its #49 holding.
  • Diadema Partners first reported a position in Relay Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.